Brilanestrant

Brilanestrant
Clinical data
Other names	GDC-0810, ARN-810, RG-6046, RO-7056118
Routes of; administration	Oral
Identifiers
	IUPAC name (2E)-3-{4-[(1E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl]phenyl}prop-2-enoic acid;
CAS Number	1365888-06-7;
PubChem CID	56941241;
ChemSpider	35308225;
UNII	9MM2R1A06R;
KEGG	D11264;
Chemical and physical data
Formula	C26H20ClFN2O2
Molar mass	446.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=C(C1=CC=C(C=C1)C=CC(=O)O)C2=CC3=C(C=C2)NN=C3)C4=C(C=C(C=C4)F)Cl;
	InChI InChI=1S/C26H20ClFN2O2/c1-2-21(22-10-9-20(28)14-23(22)27)26(18-8-11-24-19(13-18)15-29-30-24)17-6-3-16(4-7-17)5-12-25(31)32/h3-15H,2H2,1H3,(H,29,30)(H,31,32)/b12-5+,26-21+; Key:BURHGPHDEVGCEZ-KJGLQBJMSA-N;

Brilanestrant (INN) (developmental code names GDC-0810, ARN-810, RG-6046, RO-7056118) is a nonsteroidal combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) that was discovered by Aragon Pharmaceuticals and was under development by Genentech for the treatment of locally advanced or metastatic estrogen receptor (ER)-positive breast cancer.

Development of brilanestrant was discontinued by Roche in April 2017. It reached phase II clinical trials for the treatment of breast cancer prior to the discontinuation of its development.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.